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Astroprincin (APCN, FAM171A1) is a recently characterized transmembrane glycoprotein
that is abundant in brain astrocytes and is overexpressed in some tumors. However,
the expression and role of APCN is unknown in oral tongue squamous cell carcinoma
(OTSCC). Aim of this study was to investigate the expression of APCN in OTSCC tissue
samples and to analyze possible association of APCN with clinicopathological features
and survival rates. This study included 76 patients treated for OTSCC. Expression of
APCN in OTSCC tissue sections was examined by immunohistochemistry with a rabbit
polyclonal antibody (MAP346) against APCN. All tumors were scored for intensity and
percentage of APCN staining at the superficial, middle, and invasive front areas. High
expression of APCN was significantly associated with increased tumor size (P = 0.013)
and with OTSCC recurrence (P= 0.026). In this pilot study, we observed that the amount
of APCN is associated with the size and recurrence of OTSCC. This finding suggests a
role of APCN during OTSCC progression.
Keywords: oral tongue squamous cell carcinoma (OTSCC), recurrence, tumor progression, astroprincin (APCN),
FAM171A1
INTRODUCTION
Oral squamous cell carcinoma (OSCC) is a highly prevalent epithelial malignancy of the oral cavity
and afflicts over 300,000 people annually [1]. Early detection and location of the tumor for OSCC
has been associated with overall survival rate [2]. Oral tongue squamous cell carcinoma (OTSCC)
is generally presented with aggressive clinical behavior and worse prognosis than other sites of
the oral cavity [3]. The rationale for this is rich lymphatic network and muscularized structure of
the tongue that accelerates invasion and lymph node metastasis [3]. Recent studies have indicated
rise in the incidence of OTSCC among younger men [4]. The overall incidence of OTSCC has also
increased and constitute 25–40% of oral carcinomas [3, 5]. Recent research in OTSCC has primarily
focused to explore new biomarkers and additional risk factors [6].
Despite the progress in diagnosis and treatment of OTSCC, improvement in survival rates
among patients with advanced stages have remained modest [7]. The prognosis of oral cancer
is commonly estimated through clinical TNM classification [8]. However, the prognosis and
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response to treatment often deviate considerably between
patients with the same TNM stage [9, 10]. Although numerous
molecular prognostic biomarkers have been assessed in the last
decade, none are currently in clinical pathology practice [11,
12]. Therefore, there is still a need to identify reliable markers
that provide prognostic evaluation of OTSCC to facilitate
treatment planning.
Rasila et al. [13] recently characterized a novel endogenous
protein called astroprincin (APCN, also known as FAM171A1)
that is abundant in brain astrocytes. APCN is an evolutionarily
conserved 98-kDa transmembrane type I glycoprotein. APCN
is expressed in placental trophoblasts, kidneys, pancreas and
heart muscle [13]. APCN is also expressed in some malignancies,
FIGURE 1 | Astroprincin (APCN) expression in OTSCC at the invasive front. (A) An example of high percentage (>85%) and intensity at invasive front. (B) low
percentage (<85%) and intensity at invasive front.
such as nodular melanoma and lobular breast cancer [13].
Higher APCN expression was seen in the tumor invasive
front than in the intra-tumoral cells [13]. The authors
showed that upregulated APCN expression induced an invasive
growth pattern, with sprouting of slender-like projections
in melanoma cells [13]. Furthermore, FAM171A1 (APCN)
expression has also recently been shown to correlate with invasive
phenotypes and poor overall survival in triple-negative breast
cancers [14].
Our present study was conducted to investigate the expression
of APCN in OTSCC tissue samples and to analyze the possible
association between APCN and clinicopathological features and
survival rates of OTSCC patients.
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MATERIALS AND METHODS
Patients and Clinical Data
This study included 114 patients with OTSCC. Histopathological
data of the patients collected from the pathology reports included
tumor grade (grade I-III). Clinical data obtained from the
department of otorhinolaryngology (Oulu University Hospital)
included age, sex, status of the patient (alive or deceased), cause
of death, follow-up time (months), clinical stage of the tumor
(cT), and lymph node status (cN). Out of the original 114 cases,
38 were excluded due to incomplete clinical data available. The
FIGURE 2 | Kaplan–Meier curves of OTSCC patient survival divided into two groups corresponding to immunoexpression of APCN at 85% cut-off point (<85% vs.
>85%). Overall survival (OS) for percentage of APCN at the invasive front (A); Disease-specific survival (DSS) for percentage of APCN at the invasive front (B).
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number of included OTSCC cases in the final analyses was
thus 76.
Astroprincin Immunohistochemistry
Tumor paraffin blocks of 114 postoperative resected OTSCC
cases were collected from the pathology department. Tissue
sections of 4-µm thickness were mounted on slides and
allowed to dry overnight at 37◦C. The slides were subjected
to deparaffinization and rehydration. The primary polyclonal
antibody MAP346 was produced as described by Rasila et al. [13]
MAP346 was diluted 1:750 and incubated for 15min. Staining
was performed as previously described by Rasila et al. [13] using
Bond Polymer Refine Detection kit and Leica Bond RX staining
automat. Dako’s rabbit negative control X0903 was first used in
the same concentration as antibody dilution. For the negative
control, the primary antibody was omitted, and for the positive
control was breast cancer tissue sections which have previously
shown to be positive for MAP346 (Rasila et al. [13]).
Evaluation of Astroprincin
Immunoexpression
APCN immunoexpression was examined with a staining reaction
of light or dark brown color in the cytoplasm and nuclei of
OTSCC cells. The dark brown staining was considered high
immunoexpression and light brown staining was considered
low expression. The immunoexpression between high and low
was considered moderate. For evaluation, both nuclear and
cytoplasmic expression were analyzed and the average fraction
of stained cancer cells was calculated.
For scoring, all slides were classified into the following two
main factors based on the proportion of positively stained cancer
cells by the APCN antibody: intensity and percentage of staining
by APCN for OTSCC specimens. All tumors were divided into
three areas for evaluation of APCN, namely (1) superficial, (2)
middle, and (3) invasive front. Each of the three areas were
categorized into the following three scores based on APCN
staining intensity: low intensity (scored 1), moderate intensity
(scored 2), and high intensity (scored 3). Different cut-off points
TABLE 1 | Clinicopathological characteristics of 76 patients with OTSCC in relation to high and low percentage of APCN at the invasive front.
Variable Total High APCN percentage at
invasive front











< 60 24 (31.6%) 23 (95.8%) 1 (4.2%)
> 60 52 (68.4%) 45 (86.5%) 7 (13.5%)
Gender 0.085
Female 31 (40.79%) 30 (96.8%) 1 (3.2%)
Male 45 (59.21%) 38 (84.45%) 7 (15.55%)
WHO Grade 0.630
I 16 (21.05%) 15 (93.75%) 1 (6.25%)
II 45 (59.21%) 39 (86.7%) 6 (13.30%)
III 15 (19.74%) 14 (93.3%) 1 (6.7%)
cTNM Stage 0.084
Early stage (I and II) 57 (75%) 53 (92.98%) 4 (7.02%)
Late stage (III and IV) 19 (25%) 15 (78.95) 4 (21.05%)
cT 0.013
1 28 (36.8%) 26 (92.86%) 2 (7.14%)
2 34 (44.7%) 32 (94.1%) 2 (5.9%)
3 10 (13.15%) 6 (60%) 4 (40%)
4 4 (5.35%) 4 (100%) 0
cN 0.724
0 57 (75%) 51 (89.47%) 6 (10.53%)
1 14 (18.4%) 13 (92.85%) 1 (7.15%)
2 5 (6.6%) 4 (80%) 1 (20%)
Recurrence* 0.026
No 44 (64.70%) 36 (81.81%) 8 (18.19%)
Yes 24 (35.30%) 24 (100%) 0
Clinical stage of the tumour (cT), and lymph node status (cN).
*Recurrence data of the eight cancer cases were not available. P values in bold are statistically significant.
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(10, 20, 30, 50, and 85%) were used to evaluate the association
of APCN percentage score with clinicopathologic characteristics.
The distribution of stained tumor by APCN for each of three
areas were assessed on the basis of most relevant percentage
(<85% and >85%) for low and high percentage score (Figure 1).
Two investigators (AW and AA) evaluated all scanned
specimens independently with QuPath software Version 0.1.2,
which is an open-source software for digital pathology image
analysis. In case of disagreement, the samples were re-evaluated
to determine a consistent final score. The Kappa coefficient of
agreement between the observers was 0.773. Observers were
blinded to all clinical data.
Statistical Analysis
The significance level was observed higher at the invasive front
than the other two regions, and therefore it was selected for all
statistical analyses in relation to clinicopathological variables and
survival analyses. The association between clinicopathological
characteristics (age, gender, grade, stage, cT, cN, and recurrence)
and the expression of APCN intensity and percentage at the
invasive front was analyzed with cross-tabulation.
The survival analyses performed included overall survival
(OS; refers to the time from surgery to death or last follow-up)
and disease-specific survival (DSS; refers to the time from surgery
to death from OTSCC or last follow-up). OS and DSS curves
were constructed with the Kaplan–Meier method. A log-rank
test was used to compare the statistical significance between the
APCN groups (Figure 2). Cox proportional hazard models were
used to obtain the unadjusted hazard ratios (HRs) and their 95%
confidence intervals (CIs). All statistical analyses were performed
with IBM SPSS Statistics (version 24) software.
RESULTS
Forty-five (59.21%) of the OTSCC patients were males and 31
(40.79%) were females (Table 1). Early-stage (T1 and T2) tumors
were observed in 57 (75%) patients and late-stage (T3 and T4)
tumors in 19 (25%) patients (Table 1). The median follow-up
period was 35.8 months and range was 0-121 months.
Relationship Between APCN Expression,
Clinicopathologic Characteristics, and
Survival
We observed a significant association between tumor size and a
high percentage of APCN expression at the tumor invasive front
(P = 0.013). Enhanced expression of APCN at the invasive front
was significantly associated with disease recurrence in the cross-
tabulation analysis (P = 0.026; Table 1). We did not observe
a significant relationship between APCN expression intensity
and any other clinicopathological characteristics (P > 0.05). In
univariable analysis (Table 2), APCN expression did not have
prognostic significance for OS (HR 1.24, 95% CI 0.16–9.60; P
= 0.840) or for DSS (HR 1.04, 95% CI 0.132–8.24; P = 0.970),
(Figure 2).
TABLE 2 | Survival analyses of 76 cases with OTSCC.
Variable Overall survival (OS) Disease-specific
survival (DSS)
HR (95% CI) HR (95% CI)
Percentage of APCN at IF
Low (<85%) 1 1
High (>85%) 1.24 (0.16–9.60) 1.04 (0.132–8.24)
P = 0.840 P = 0.970
Intensity of APCN at IF
Low 1 1
Moderate 0.83 (0.10–6.90) 0.724 (0.08–6.23)
P = 0.860 P = 0.770
High 0.30 (0.035–2.65) 0.285 (0.03–2.56)
P = 0.280 P = 0.260
Age
≤60 1 1
>60 1.76 (0.48–6.40) 1.20 (0.31–4.65)
P = 0.390 P = 0.790
Gender
Female 1 1
Male 0.39 (0.12–1.19) 0.43 (0.12–1.55)
P = 0.100 P = 0.200
cTNM Stage
I-II 1 1
III-IV 0.85 (2.33–3.10) 0.71 (0.15–3.36)
P = 0.800 P = 0.670
Grade (WHO)
I 1 1
II 1.64 (0.34–7.74) 2.31 (0.27–19.23)
P = 0.530 P = 0.440
III 2.34 (0.39–14.05) 4.38 (0.45–42.20)
P = 0.350 P = 0.200
cT
T1 1 1
T2 1.31 (0.38–4.51) 0.94 (0.25–3.50)
P = 0.660 P = 0.925
T3 0.70 (0.08–6.34) 0.72 (0.080–6.42)
P = 0.760 P = 0.765
T4 2.51 (0.28–22.65) NA
P = 0.410 NA
cN
N0 1 1
N1 0.77 (0.165–3.56) 1.18 (0.24–5.85)
P = 0.735 P = 0.840
N2 2.90 (0.6213.45) 4.05 (0.81–20.13)
P = 0.175 P = 0.085
Recurrence*
No 1 1
Yes 2.19 (0.67–7.19) 2.35 (0.632–8.77)
P = 0.195 P = 0.200
The overall survival and disease specific analyses present the prognostic significance of
Astroprincin (APCN) at the invasive front (IF) and other clinicopathologic variables.
*Recurrence data of the eight cancer cases were not available.
IF, invasive front. NA, not available.
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DISCUSSION
APCN has emerged evolutionarily as a highly conserved type
1 transmembrane glycoprotein that regulates cell cytoskeletal
dynamics and tumor cell invasion [13]. Elevated expression of
APCN has been reported in lobular and triple-negative breast
cancer cells and at the invasive front of nodular melanoma
[13, 14]. Here we investigated for the first time APCN expression
in OTSCC and observed that it was associated with tumor size
and recurrence. However, the median follow-up time was only
35.8 months and there were missing values of recurrence which
are the main limitations in this study.
All cases in the cohort of our study had been treated before
2017 and lacked information on extra-nodal extension of many
cases which is part of the N-category in the 8th edition of
American Joint Committee on Cancer (AJCC). Therefore, cohort
of this study was staged according to the 7th edition of (AJCC).
Few studies have evaluated APCN in different tumors [13, 15].
We hypothesized that APCNmight have a role in the progression
of OTSCC. Although we observed a significant association
between APCN expression and increased tumor size (cT), there
was no significant difference in the mortality between patients
with low and high APCN expression. However, higher expression
of APCN at the invasive front was associated with an increased
recurrence rate (P = 0.026). In contrast to our study, a high
APCN expression level was associated with invasiveness and also
poor OS in triple-negative breast cancer cells [15]. The same
study also revealed that estrogen receptor alpha regulated APCN
expression in the breast cancer cells and that the APCN gene
was associated with proliferation andmigration of triple-negative
breast cancer cells. Although its biological function is not yet
well-understood, APCN is present in astrocytes and is assumed to
be involved in brain development. Bao et al. speculated that since
APCN is expressed in the brain tissue, it may explain the frequent
tendency of triple-negative breast cancer cells to metastasize into
brain tissue [14].
The APCN gene has seven short exons at the extracellular
region [13]. The exon seven runs from outside to inside the
transmembrane stretch that is highly similar from zebra fish to
human. A long intracytoplasmic portion constitute two thirds
of the protein, specifically encoded by the large exon 8, which
also has many evolutionarily conserved regions [13]. As APCN
is involved in the regulation of actin cytoskeletal dynamics,
APCN is related to cell shape, cell sprouting, and invasive
growth of tumor cells [13]. The evidence of organized actin
cytoskeleton maintenance by the APCN is further supported
by the disappearance of actin stress fibers after downregulated
expression of endogenous APCN. Moreover, complete absence
of endogenous APCN resulted in disruption of actin dynamics,
which is required for cytokinesis [13]. Therefore, the presence of
APCN protein in the invasive front of OTSCC is most probably
also related to the invasive progression of tumor. Further
investigations are required to unravel its molecular details and
role in carcinogenesis.
In conclusion, we have shown that APCN is
immunohistologically detected in a set of OTSCC samples,
and a high amount of immunoreactive protein is related to
tumor size and recurrence. However, in this pilot study, there
was no prognostic value of APCN for OS or DSS of 76 patients.
Further evaluation of APCN in large multicenter cohorts of
OTSCC may be considered to determine whether APCN can be
used for OTSCC prognostication.
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